Archives

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors’ Microbiome Evaluation at ESCMID Global 2026

B DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity Neutropenic CD-1 mice were infected intramuscularly with… Login to continue reading Login…

Read MoreAcurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors’ Microbiome Evaluation at ESCMID Global 2026

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

B CAPLYTA® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the… Login to continue reading Login…

Read MoreCAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

B Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 4, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™… Login to continue reading Login…

Read MoreVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Boston Scientific announces participation in Bernstein’s 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results

B MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein’s 42nd Annual Strategic Decisions Conference on Wednesday, May… Login to continue reading Login…

Read MoreBoston Scientific announces participation in Bernstein’s 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results